October was a pretty brutal month for the psychedelic stock market no matter which way you look at it. While the rest of the stock market...
The article Atai Reports Q3 Financials and Business Update was originally published on Microdose. atai Life Sciences has the biggest product portfolio...
Clinical-stage biopharmaceutical company atai Life Sciences (Nasdaq: ATAI) reported financial results for the third quarter ending Sept. 30, providing...
The Women in Psychedelics Network , a network of professionals from all corners of the psychedelic industry strengthening women’s voices and providing...
Company is expanding clinical trials of its psilocybin-based medicine. The post Compass Pathways Losses Tick Up on Increased R&D appeared first on...
Despite a challenging economy, psychedelics companies have accelerated development. The post Recession Predictions Not Slowing Psychedelics Industry appeared...
Novel treatments are required. That’s where psychedelics come in. The post Psychedelic Treatment for Suicide Could be in Sight appeared first on Green...
Risk is part of investing. Even the most mature, well-established firms and stocks run the risk of declining to zero. However, that risk is even higher...
Source: Dr. Elemer Piros 10/27/2022 This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich...
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...